Middle East & Africa Prostate Cancer Nuclear Medicine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)

Name: Middle East & Africa Prostate Cancer Nuclear Medicine Market
SKU: Pharmaceuticals
Rating: 4.6 (42 reviews)

The MEA prostate cancer nuclear medicine market is expected to grow from US$ 35.66 million in 2022 to US$ 62.49 million by 2028; it is estimated to grow at a CAGR of 9.8% from 2022 to 2028.

Prostate cancer is a prevalent male malignancy that remains a major health issue. In the clinical care of patients, imaging is critical. Prostate cancer imaging provides precise disease characterization through synthesizing anatomic, functional, and molecular imaging information. Prostate cancer detection has increased due to advances in imaging technologies, such as magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT). Lesion detection and local staging have improved due to MRI. Diffusion-weighted MRI, MR spectroscopy, and dynamic contrast-enhanced MRI are among the MRI techniques used to assess function. Conventional imaging options, such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, are used for prostate cancer patients to detect organ-confined or metastatic disease for staging and prognosis. However, the use of imaging for assessing tumor grade, staging, finding minimal metastatic disease, and separating fatal from a nonlethal disease needs to be improved. Hybrid imaging approaches for diagnosis use complementary structural and morphological data to improve imaging resolution and sensitivity. For instance, the FDA approved a complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 to identify PSMA-positive lesions. After radiolabeling, this imaging agent may be used to identify PSMA-positive lesions in adult patients with mCRPC through a positron emission tomography scan.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA prostate cancer nuclear medicine market. The MEA prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.

MEA Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)

MEA Prostate cancer nuclear medicine Market Segmentation

The MEA prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the MEA prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the MEA prostate cancer nuclear medicine market in 2022. Based on PET product, the MEA prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the MEA prostate cancer nuclear medicine market in 2022. Based on end user, the MEA prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the MEA prostate cancer nuclear medicine market in 2022. Based on country, the MEA prostate cancer nuclear medicine market is segmented into Saudi Arabia, UAE, South Africa, and the rest of the MEA. The Saudi Arabia segment dominated the MEA prostate cancer nuclear medicine market in 2022.

ImaginAb; Curium; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the MEA prostate cancer nuclear medicine market.

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By Type

1.3.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product

1.3.3 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By End User

1.3.4 MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 MEA PEST Analysis

4.3 Experts Opinion

5. MEA Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics

5.1 Market Drivers

5.1.1 Surging Prevalence of Prostate Cancer

5.1.2 Soaring Demand for Early and Precise Diagnosis of Prostate Cancer

5.2 Market Restraints

5.2.1 Overpriced Related to the Prostate Cancer Diagnostics and Treatment

5.3 Market Opportunities

5.3.1 Expanding Use of Radiopharmaceuticals in Prostate Cancer

5.4 Future Trends

5.4.1 Developing Research Activities for Development of Innovative Imaging Agents

5.5 Impact Analysis

6. Prostate Cancer Nuclear Medicine Diagnostics Market– MEA Analysis

6.1 MEA Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis

7. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type

7.1 Overview

7.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)

7.3 SPECT

7.3.1 Overview

7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

7.4 PET

7.4.1 Overview

7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

8. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product

8.1 Overview

8.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)

8.3 F-18

8.3.1 Overview

8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

8.4 C-11

8.4.1 Overview

8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

8.5 GA 68 PSMA

8.5.1 Overview

8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9. MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By End User

9.1 Overview

9.2 MEA Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9.4 Clinics

9.4.1 Overview

9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

10. MEA Prostate Cancer Nuclear Medicine Diagnostics Market – By Country Analysis

10.1 MEA Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028

10.1.1 Overview

10.1.2 MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2021 & 2028 (%)

10.1.2.1 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.1.1 Overview

10.1.2.1.2 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.1.3 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.2.1.4 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.2.1.5 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.1.2.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.2.1 Overview

10.1.2.2.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.2.3 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.2.2.4 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.2.2.5 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.1.2.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.3.1 Overview

10.1.2.3.2 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.3.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.2.3.4 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.2.3.5 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.1.2.4 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.4.1 Overview

10.1.2.4.2 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.2.4.3 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.2.4.4 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.2.4.5 Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

11. Prostate Cancer Nuclear Medicine Diagnostics Market–Industry Landscape

11.1 Overview

11.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028

11.3 Inorganic Growth Strategies

11.3.1 Overview

11.4 Organic Growth Strategies

11.4.1 Overview

12. Company Profiles

12.1 ImaginAb

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Curium

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 ABX advanced biochemical compounds GmbH

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Telix Pharmaceuticals Ltd.

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Novartis AG

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Lantheus Medical Imaging, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

LIST OF TABLES

Table 1. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 2. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 3. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 4. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 5. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 6. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 7. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 8. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 9. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 10. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 11. Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 12. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 13. Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market

Table 14. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market

Table 15. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market

LIST OF FIGURES

Figure 1. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

Figure 2. MEA Prostate Cancer Nuclear Medicine Diagnostics Market, By Country

Figure 3. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Overview

Figure 4. PET Segment Held Largest Share of Type Segment in Prostate Cancer Nuclear Medicine Diagnostics Market

Figure 5. MEA is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. MEA: PEST Analysis

Figure 7. MEA Experts Opinion

Figure 8. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Impact Analysis of Drivers and Restraints

Figure 9. MEA Prostate Cancer Nuclear Medicine Diagnostics Market– Revenue Forecast and Analysis – 2020 - 2028

Figure 10. MEA Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2022 & 2028 (%)

Figure 11. MEA SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12. MEA PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13. MEA Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2022 & 2028 (%)

Figure 14. MEA F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)

Figure 15. MEA C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)

Figure 16. MEA GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)

Figure 17. MEA Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User - 2022 & 2028 (%)

Figure 18. MEA Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)

Figure 19. MEA Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)

Figure 20. MEA Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)

Figure 21. Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Key Country – Revenue (2022) (US$ ‘Million)

Figure 22. MEA: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)

Figure 23. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

Figure 24. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

Figure 25. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

Figure 26. Rest of MEA: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

Figure 27. Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA prostate cancer nuclear medicine market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the MEA prostate cancer nuclear medicine market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the MEA prostate cancer nuclear medicine market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Middle East and Africa Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and S..	May 2022
Middle East and Africa Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, En..	May 2022
Middle East and Africa In-Office Teeth Whitening Products Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product (Double-Syringe M..	May 2022

Purchase Options

Single User License

$3000

$1500

Site License

$4000

$2000

Enterprise License

$5000

$2500

GET FREE SAMPLE PDF

Inquire before Buying Inquire for Discount

Subscription Member Price: FREE

Get Subscription